• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AIkido Pharma Inc. (Amendment)

    2/14/22 3:13:25 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AIKI alert in real time by email
    SC 13G/A 1 tm226115d2_sc13ga.htm SC 13G/A

     

    CUSIP No: 008875106

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No.    1)*

     

    AIkido Pharma Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    008875106

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

    xRule 13d-1(c)

    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 008875106

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    0
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    0

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        0
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        0%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 008875106

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    0
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    0

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        0
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        0%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 008875106

     

    Item 1.

     

    (a)Name of Issuer

     

    AIkido Pharma Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    One Rockefeller Plaza, 11th Floor, New York, NY 10020

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    008875106

     

     

     

     

    CUSIP No: 008875106

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
       
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
       
    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
       
    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
       
    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

     

     

     

    CUSIP No: 008875106

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 008875106

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 11, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.
    pursuant to a Limited Power of Attorney, a copy of which was previously filed
      By: /s/ Brian Sopinsky
      Name: Brian Sopinsky
      Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 008875106

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously filed

     

     

     

    Get the next $AIKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIKI

    DatePrice TargetRatingAnalyst
    10/11/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AIKI
    SEC Filings

    See more
    • AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Dominari Holdings Inc. (0000012239) (Filer)

      12/18/23 4:05:35 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Dominari Holdings Inc. (0000012239) (Filer)

      11/13/23 6:05:12 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 10-Q filed by AIkido Pharma Inc.

      10-Q - Dominari Holdings Inc. (0000012239) (Filer)

      11/6/23 4:47:02 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AIkido Pharma Inc.

      SC 13D - Dominari Holdings Inc. (0000012239) (Subject)

      12/28/23 4:15:22 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

      SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

      12/28/23 4:05:18 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

      SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

      7/6/23 4:30:08 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Financials

    Live finance-specific insights

    See more
    • AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

      NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease.  The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.  This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease. We believe that one of the biggest breakthroughs in the study of depression has been the ob

      6/23/21 10:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:33 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:36 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/22/23 6:00:41 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dominari Holdings Provides Update on Share Repurchase Program

      NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part

      12/28/22 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

      NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C

      12/22/22 8:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

      Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita

      11/28/22 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AIKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AIKI
    Leadership Updates

    Live Leadership Updates

    See more
    • HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

      HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00

      10/11/21 6:14:44 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:33 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:36 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/26/23 6:43:23 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Inc. Appoints New Director, Soo Yu

      New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.  Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens t

      6/10/22 4:15:00 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

      NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public.  AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00.  As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad

      9/14/21 9:22:00 AM ET
      $AIKI
      $DATS
      Specialty Chemicals
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications
    • AIkido Pharma Provides Business Update

      NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our

      4/5/21 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary